Titan Pharmaceuticals Stock Beta
| TTNP Stock | USD 6.71 0.14 2.04% |
Titan Pharmaceuticals fundamentals help investors to digest information that contributes to Titan Pharmaceuticals' financial success or failures. It also enables traders to predict the movement of Titan Stock. The fundamental analysis module provides a way to measure Titan Pharmaceuticals' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Titan Pharmaceuticals stock.
Titan | Beta |
Titan Pharmaceuticals Company Beta Analysis
Titan Pharmaceuticals' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Titan Pharmaceuticals Beta | 1.35 |
Most of Titan Pharmaceuticals' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Titan Pharmaceuticals is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Titan Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Titan Pharmaceuticals is extremely important. It helps to project a fair market value of Titan Stock properly, considering its historical fundamentals such as Beta. Since Titan Pharmaceuticals' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Titan Pharmaceuticals' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Titan Pharmaceuticals' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Titan Pharmaceuticals has a Beta of 1.346. This is 56.51% higher than that of the Pharmaceuticals sector and 3.17% lower than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Titan Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Titan Pharmaceuticals' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Titan Pharmaceuticals could also be used in its relative valuation, which is a method of valuing Titan Pharmaceuticals by comparing valuation metrics of similar companies.Titan Pharmaceuticals is currently under evaluation in beta category among related companies.
Titan Pharmaceuticals Institutional Holders
Institutional Holdings refers to the ownership stake in Titan Pharmaceuticals that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Titan Pharmaceuticals' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Titan Pharmaceuticals' value.| Shares | Wells Fargo & Co | 2023-09-30 | 84.0 | Blackrock Inc | 2023-09-30 | 60.0 | Advisor Group Holdings, Inc. | 2023-09-30 | 50.0 | Global Wealth Strategies & Associates | 2023-12-31 | 40.0 | Morgan Stanley - Brokerage Accounts | 2023-09-30 | 16.0 | Westside Investment Management, Inc. | 2023-09-30 | 4.0 | Ubs Group Ag | 2023-09-30 | 4.0 | Qube Research & Technologies | 2023-09-30 | 4.0 | Mcclarren Financial Advisors, Inc. | 2023-09-30 | 3.0 | Bb&t Corp. | 2023-09-30 | 625.1 K | Renaissance Technologies Corp | 2023-09-30 | 135.7 K |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Titan Pharmaceuticals will likely underperform.
Titan Fundamentals
| Return On Equity | -1.39 | ||||
| Return On Asset | -0.75 | ||||
| Operating Margin | (39.55) % | ||||
| Current Valuation | (64.06 K) | ||||
| Shares Outstanding | 914.23 K | ||||
| Shares Owned By Insiders | 45.46 % | ||||
| Shares Owned By Institutions | 5.51 % | ||||
| Number Of Shares Shorted | 10.18 K | ||||
| Price To Earning | (3.60) X | ||||
| Price To Book | 1.00 X | ||||
| Price To Sales | 36.07 X | ||||
| Revenue | 184 K | ||||
| Gross Profit | (4.37 M) | ||||
| EBITDA | (7.17 M) | ||||
| Net Income | (5.57 M) | ||||
| Cash And Equivalents | 6.42 M | ||||
| Cash Per Share | 0.44 X | ||||
| Total Debt | 565 K | ||||
| Debt To Equity | 0.04 % | ||||
| Current Ratio | 3.06 X | ||||
| Book Value Per Share | 8.50 X | ||||
| Cash Flow From Operations | (7.09 M) | ||||
| Short Ratio | 0.67 X | ||||
| Earnings Per Share | (7.41) X | ||||
| Target Price | 7.0 | ||||
| Beta | 1.35 | ||||
| Market Capitalization | 6.13 M | ||||
| Total Asset | 8.09 M | ||||
| Retained Earnings | (391.83 M) | ||||
| Working Capital | 6.57 M | ||||
| Current Asset | 12.24 M | ||||
| Current Liabilities | 4.85 M | ||||
| Net Asset | 8.09 M |
About Titan Pharmaceuticals Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Titan Pharmaceuticals's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Titan Pharmaceuticals using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Titan Pharmaceuticals based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
When determining whether Titan Pharmaceuticals is a good investment, qualitative aspects like company management, corporate governance, and ethical practices play a significant role. A comparison with peer companies also provides context and helps to understand if Titan Stock is undervalued or overvalued. This multi-faceted approach, blending both quantitative and qualitative analysis, forms a solid foundation for making an informed investment decision about Titan Pharmaceuticals Stock. Highlighted below are key reports to facilitate an investment decision about Titan Pharmaceuticals Stock:Check out Titan Pharmaceuticals Piotroski F Score and Titan Pharmaceuticals Altman Z Score analysis. To learn how to invest in Titan Stock, please use our How to Invest in Titan Pharmaceuticals guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Complementary Tools for Titan Stock analysis
When running Titan Pharmaceuticals' price analysis, check to measure Titan Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Titan Pharmaceuticals is operating at the current time. Most of Titan Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Titan Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Titan Pharmaceuticals' price. Additionally, you may evaluate how the addition of Titan Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Commodity Directory Find actively traded commodities issued by global exchanges | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Money Flow Index Determine momentum by analyzing Money Flow Index and other technical indicators | |
| Sign In To Macroaxis Sign in to explore Macroaxis' wealth optimization platform and fintech modules | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. |
Is Titan Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Titan Pharmaceuticals. If investors know Titan will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Titan Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (7.41) | Revenue Per Share 0.245 | Quarterly Revenue Growth (1.00) | Return On Assets (0.75) | Return On Equity (1.39) |
The market value of Titan Pharmaceuticals is measured differently than its book value, which is the value of Titan that is recorded on the company's balance sheet. Investors also form their own opinion of Titan Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Titan Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Titan Pharmaceuticals' market value can be influenced by many factors that don't directly affect Titan Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Titan Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Titan Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Titan Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.